ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. (ticker: ZVSA) is an OTC-listed pharmaceutical preparations company. DredgeCap's structured extraction of ZVSA's SEC filings surfaces 8 active risk signals, including 3 delisting/deregistration signals, 3 late-filing signals, and 2 auditor-change signals. ZVSA reported no tagged revenue in revenue and -$1.79M for the period ending 2026-03-31, with operating cash flow of -$799K. Cash and equivalents stood at $303K (down 81.2% year-over-year). Total assets of $742K are exceeded by total liabilities of $14.87M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

ZVSA Cash Runway

Months-of-runway analysis for ZVSA, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on ZVSA

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.